Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line therapy of glioblastoma multiforme with standard of care and dendritic cell vaccination
2009-013406-13Phase 2Completed
- Sponsor
- Masaryk University
- Start
- Aug 2009
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of murcidencel in glioblastoma (GBM), sponsored by Masaryk University. Primary endpoint: Toxicity of DC vaccination. Started Aug 2009; status: completed.
02
Drugs
murcidencel
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2009-013406-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013406-13.